Voclosporin & Sparsentan in FSGS & IgAN — PatSnap Eureka
Voclosporin & Sparsentan: Next-Generation Approaches in FSGS and IgA Nephropathy
FSGS and IgAN collectively drive a major share of global ESRD burden. This patent-derived intelligence report maps the innovation landscape around calcineurin inhibitor alternatives, dual endothelin-angiotensin antagonists, complement pathway inhibitors, and emerging targets — from voclosporin dosing protocols to the suPAR/podocyte axis.
Two High-Burden Glomerular Diseases with Unmet Therapeutic Need
FSGS is a heterogeneous glomerular disorder characterized by segmental sclerosis, nephrotic-range proteinuria, and progressive loss of kidney function. Massive proteinuria exceeding 10–15 g/day leads to ESRD within 2–3 years, with a survival rate of only 45% in such patients. The annual FSGS incidence is cited at 0.2 to 1.8 per 100,000 persons/year. APOL1 genetic variants confer elevated ESRD risk particularly in patients of African ancestry, a stratification signal highlighted across multiple Chinook Therapeutics and Genzyme/Sanofi filings.
IgA nephropathy is the most common form of glomerulonephritis worldwide, driven by IgA deposition in the mesangium causing inflammation, hematuria, proteinuria, and progressive glomerular injury. Until recently, treatment options remained largely limited to nonspecific immunosuppression, and no approved therapies existed for FSGS until recently. The innovation pipeline now encompasses at least seven distinct mechanistic approaches, from calcineurin inhibition to complement pathway blockade.
Explore the full patent landscape across both indications using PatSnap Eureka's life sciences intelligence platform, which integrates patent data with literature signals to surface competitive white spaces. The PatSnap Life Sciences solution is purpose-built for drug discovery and IP strategy teams working in nephrology and rare disease.
Key Agents and Mechanistic Approaches in the FSGS & IgAN Pipeline
Patent-derived intelligence across seven distinct mechanistic clusters, from next-generation CNI dosing to novel ion channel pharmacology.
Voclosporin — Pharmacodynamic Dosing Protocol
Voclosporin is a cyclosporin A analogue developed by Aurinia Pharmaceuticals with an improved pharmacodynamic profile relative to legacy CNIs. At least seven active Aurinia patent filings across WO, CA, IL, MX, BR, and US jurisdictions cover dose-titration protocols in 7.9 mg BID increments, biopsy-based monitoring (medial arteriolar hyalinosis), and triple-combination with MMF and tapering corticosteroids. Doses as low as 7.9–15.8 mg BID were reported effective, outperforming 39.5 mg BID. IP strategy is entirely method-of-use centered — not composition-of-matter.
≥7 active patents · Method-of-use IP strategySparsentan — Dual Hemodynamic Blockade
Sparsentan (Travere Therapeutics, formerly Retrophin) is a biphenyl sulfonamide compound simultaneously blocking ETA and AT1 receptors, reducing intraglomerular pressure and podocyte injury through complementary hemodynamic mechanisms. Patent text cites comparative UP/C ratio reductions vs. irbesartan across dose groups (200 mg/day and 400 mg/day). FSGS-CT (n=109) and NEPTUNE (n=118) cohort data are explicitly referenced, stratifying patients by proteinuria tier. Sparsentan is also listed as a combination partner with pyridazinone compounds in Goldfinch Bio filings.
FSGS-CT n=109 · NEPTUNE n=118 cohort data citedAtrasentan — Most Patent-Dense Asset in Dataset
Atrasentan (Chinook Therapeutics, now Novartis) is a highly selective ETA receptor antagonist with a Ki of approximately 34 pM. Twelve patent records across JP, TW, CN, ID, and WO jurisdictions cover both FSGS and IgAN indications, with filings as recent as 2026. Claimed mechanisms include ETA blockade reducing glomerular endothelin-1-driven vasoconstriction, mesangial PDGF signaling suppression (PIK3R1, PDGFRA, NFKBIA, PDGFB, NFKB1, MAP3K1 pathway components), anti-fibrotic effects, eGFR stabilization, and ESRD delay. Dosing in IgAN specified at 0.20 mg to 1.5 mg per administration.
Ki ~34 pM at ETA · 12 patents · 2021–2026Anti-MASP-2 (OMS646) — Steroid-Sparing in IgAN
University of Leicester and Omeros Corporation co-own a PCT-derived patent family covering MASP-2 inhibitory antibody OMS646 for reducing proteinuria in IgAN. The mechanism involves selective inhibition of MASP-2-dependent complement activation, preserving classical and alternative pathways. Dosing: approximately 4 mg/kg IV once weekly for at least 12 weeks, or 180–725 mg fixed dose. Retrieved filings describe a steroid-sparing co-primary endpoint — treatment reduces or eliminates the need for steroid therapy. Active across WO, AU, CA, SG, CN, and US jurisdictions.
4 mg/kg IV weekly · 12-week regimen · Steroid-sparingsuPAR/β3 Integrin Axis — Fragmented but Active IP
Elevated serum suPAR activates podocyte β3 integrin, triggering FSGS pathology. At least five independent assignees — University of Miami, UC Regents, Massachusetts General Hospital, Walden Biosciences, and Joshen Riser — have filed patents targeting this axis. Strategies include anti-uPAR/anti-suPAR monoclonal antibodies, ex vivo removal of suPAR from circulation, and inhibition of myeloid progenitor-derived suPAR production. Pre-transplant suPAR levels are described as predictive of FSGS recurrence in renal grafts. The scattered assignee landscape suggests no single commercial leader has claimed this space.
5 independent assignees · Predominantly preclinicalFresolimumab — APOL1-Variant FSGS (Inactive)
Genzyme Corporation holds an inactive patent family (CA, TW, JP) covering IV administration of fresolimumab, an anti-TGF-β antibody, in primary FSGS patients carrying APOL1 variants. This approach targets the fibrogenic TGF-β pathway driving progressive glomerulosclerosis. Filing inactivity across all jurisdictions may signal program discontinuation. APOL1 variant stratification is cited as the patient enrichment approach, representing an unaddressed biomarker-enrichment opportunity that could be separately pursued through companion diagnostic IP.
Inactive filings · APOL1 enrichment strategyPatent Landscape: Key Metrics at a Glance
Quantitative signals derived from patent record analysis via PatSnap Eureka. All values sourced directly from retrieved patent data.
Patent Filing Activity by Assignee
Chinook Therapeutics (now Novartis) leads with 12 records; Aurinia Pharmaceuticals holds 8 method-of-use patents — together accounting for the majority of commercial IP in this dataset.
Mechanistic Target Distribution in FSGS & IgAN Pipeline
ETA receptor is the most IP-contested target, represented by atrasentan and sparsentan filings. Calcineurin and complement pathways follow as the next most active clusters.
Agent-by-Agent Comparison: Mechanisms, Data, and IP Status
All data derived from patent records in the PatSnap Eureka dataset. Development stage inferred from filing specificity and clinical endpoint detail.
| Agent | Mechanism | Indication(s) | Key Assignee | Patent Records | Dev. Stage Signal |
|---|---|---|---|---|---|
| Atrasentan | Selective ETA antagonist (Ki ~34 pM) | FSGS, IgAN | Chinook / Novartis | 12 (JP, TW, CN, ID, WO) | Clinical Translation |
| Voclosporin | CNI — pharmacodynamic dosing protocol | Lupus nephritis, FSGS, IgAN | Aurinia Pharmaceuticals | 8 (WO, CA, IL, MX, BR, US) | Near-Commercial |
| OMS646 (anti-MASP-2) | MASP-2 complement lectin inhibition | IgAN, lupus nephritis | Univ. Leicester / Omeros | 6 (WO, AU, CA, SG, CN, US) | Phase 1/2 Signal |
| Sparsentan | Dual ETA/AT1 antagonist | FSGS, IgAN | Travere Therapeutics | 1 (CN) | Phase 2 Data Cited |
| Anti-suPAR mAbs | suPAR/β3 integrin axis blockade | FSGS | UC Regents, Univ. Miami, MGH | 5 (JP, WO, US) | Preclinical |
| Fresolimumab | Anti-TGF-β antibody | APOL1-variant FSGS | Genzyme / Sanofi | 3 (CA, TW, JP) | Inactive / Discontinued? |
IP Strategy Signals and Competitive White Spaces
Key strategic implications derived from patent record analysis. All observations traceable to retrieved patent data.
ETA Axis Is the Most IP-Contested Target
Chinook Therapeutics (atrasentan) and Travere Therapeutics (sparsentan) hold complementary but distinct claims — atrasentan is selective for ETA while sparsentan is dual ETA/AT1. This creates competitive differentiation but also freedom-to-operate considerations for follow-on programs targeting these same indications across FSGS and IgAN.
Aurinia's Voclosporin IP Is Method-of-Use, Not Composition
The dense cluster of pharmacodynamic dosing protocol patents — CNI nephrotoxicity minimization, biopsy-based monitoring, 7.9 mg BID titration — signals a lifecycle management and differentiation strategy likely designed to extend commercial exclusivity beyond any composition patent. Competitors seeking to use voclosporin-class CNIs in proteinuric kidney diseases will need to design around these protocol claims.
suPAR Axis: Active but Fragmented — Acquisition Opportunity
At least five independent assignees hold suPAR-related filings, but the scattered assignee landscape and predominance of inactive/preclinical filings suggests this mechanism has not yet been clinched by a single commercial leader — representing a potential partnership or acquisition opportunity for organizations tracking the FSGS innovation landscape.
Complement Inhibition in IgAN: Under-Protected White Space
The University of Leicester/Omeros MASP-2 family and Alexion's complement factor D inhibitor filing are the primary complement-targeting entries in this dataset. Given the emerging understanding of lectin and alternative pathway dysregulation in IgAN, this mechanistic space may be underexploited commercially and represents a potential white space for novel biologics or small molecules targeting the IgAN complement cascade.
Multi-Agent Strategies and Next-Wave Targets
All Aurinia voclosporin filings describe an explicitly validated triple-combination protocol: voclosporin combined with mycophenolate mofetil (MMF) and tapering corticosteroids (prednisone), with the corticosteroid dose reduced across the treatment period. This multimodal approach appears designed to enable calcineurin inhibition at lower, less nephrotoxic exposures.
Goldfinch Bio's 2022 CN filing discloses combination of Formula A pyridazinone compounds with sparsentan, as well as with tacrolimus, cyclosporin A, and rituximab, suggesting exploration of novel mechanisms alongside established backbone agents in FSGS and IgAN. Both sparsentan (dual ETA/AT1) and the comparator context of atrasentan signal that dual-pathway RAAS + endothelin blockade is a preferred combination strategy for maximizing proteinuria reduction while controlling hemodynamic risk. Learn more about novel chemical scaffold discovery with PatSnap's chemistry intelligence tools.
The European Medicines Agency and FDA regulatory pathways for rare kidney diseases are increasingly accommodating accelerated approval based on proteinuria endpoints, making the clinical translation signals in these patent filings particularly actionable. Explore how PatSnap's patent analytics can surface regulatory filing patterns alongside IP data.
Voclosporin, Sparsentan & FSGS/IgAN Pipeline — Key Questions Answered
Voclosporin is a cyclosporin A analogue developed by Aurinia Pharmaceuticals with an improved pharmacodynamic profile relative to legacy CNIs. Aurinia patent filings are directed to pharmacodynamic dosing protocols that maximize efficacy in proteinuric kidney diseases while minimizing CNI nephrotoxicity. Dose adjustments are made in 7.9 mg BID increments, and doses as low as 7.9–15.8 mg BID were reported effective, outperforming 39.5 mg BID.
Sparsentan is characterized as simultaneously blocking ETA (endothelin A) and AT1 (angiotensin II type 1) receptors, reducing intraglomerular pressure and podocyte injury through complementary hemodynamic mechanisms. Retrieved patent text cites sparsentan data showing reduction in urine protein-to-creatinine (UP/C) ratio from baseline vs. irbesartan comparator in patient cohorts across dose groups (200 mg/day and 400 mg/day).
Atrasentan is a highly selective ETA receptor antagonist with a Ki of approximately 34 pM at ETA, whereas sparsentan is a dual ETA/AT1 antagonist. Atrasentan is selective for ETA while sparsentan adds concurrent AT1 blockade, potentially providing additive anti-proteinuric benefit via dual hemodynamic mechanisms. Chinook Therapeutics holds at least 12 patent records covering atrasentan across JP, TW, CN, and ID jurisdictions.
Elevated serum suPAR (soluble urokinase receptor) activates podocyte β3 integrin, triggering FSGS pathology. Multiple independent research groups including the University of Miami, UC Regents, and Massachusetts General Hospital have separately filed patents targeting the suPAR axis in FSGS. Pre-transplant suPAR levels are described as predictive of FSGS recurrence in renal grafts.
APOL1 genetic variants are specifically highlighted as conferring elevated ESRD risk in patients of African ancestry in multiple Chinook Therapeutics filings and the Genzyme/Sanofi TGF-β antagonist series. Multiple filings cite APOL1 as a risk stratification tool, but no single program in this dataset has built primary claims around APOL1-guided treatment selection — a gap that could be strategically filled by companion diagnostic or precision medicine IP.
The anti-MASP-2 antibody OMS646, co-developed by University of Leicester and Omeros Corporation, involves selective inhibition of MASP-2-dependent complement activation, preserving the classical and alternative pathways. Dosing regimen is approximately 4 mg/kg IV once weekly for at least 12 weeks. Retrieved filings also describe a steroid-sparing effect: treatment reduces or eliminates the need for steroid therapy.
Still have questions? Let PatSnap Eureka answer them instantly from patent and literature data.
Ask PatSnap Eureka About FSGS & IgANAccelerate Your Nephrology Drug Discovery & IP Strategy
Join 18,000+ innovators already using PatSnap Eureka to surface competitive signals, map patent white spaces, and track pipeline activity in FSGS, IgAN, and rare kidney disease.
References
- Protocol to minimize calcineurin inhibitor nephrotoxicity — Aurinia Pharmaceuticals Inc., 2023, IL [Patent]
- Protocol to minimize calcineurin inhibitor nephrotoxicity — Aurinia Pharmaceuticals Inc., 2022, WO [Patent]
- Voclosporin composition for treating proteinuric kidney disease — Aurinia Pharmaceuticals Inc., 2020, IL [Patent]
- Protocol to minimize calcineurin inhibitor nephrotoxicity — Aurinia Pharmaceuticals Inc., 2023, US [Patent]
- Protocol to minimize calcineurin inhibitor nephrotoxicity — Aurinia Pharmaceuticals Inc., 2022, CA [Patent]
- Protocol to minimize calcineurin inhibitor nephrotoxicity — Aurinia Pharmaceuticals Inc., 2023, MX [Patent]
- Protocol to Minimize Nephrotoxicity of Calcineurin Inhibitor — Aurinia Pharmaceuticals Inc., 2023, BR [Patent]
- Improved protocol for treatment of lupus nephritis — Aurinia Pharmaceuticals Inc., 2018, CA [Patent]
- Methods of treating IgA nephropathy with atrasentan — Chinook Therapeutics U.S., Inc., 2021, TW [Patent]
- Methods of treating IgA nephropathy with atrasentan — Chinook Therapeutics U.S., Inc., 2025, TW [Patent]
- Methods of treating IgA nephropathy with atrasentan — Chinook Therapeutics, Inc., 2026, TW [Patent]
- How to treat IgA nephropathy with atrasentan — Chinook Therapeutics, Inc., 2025, JP [Patent]
- How to treat IgA nephropathy with atrasentan — Chinook Therapeutics, Inc., 2023, JP [Patent]
- Methods of treating IgA nephropathy with atrasentan — Chinook Therapeutics, Inc., 2025, JP [Patent]
- How to treat IgA nephropathy with atrasentan — Chinook Therapeutics, Inc., 2026, JP [Patent]
- Methods for treating focal segmental glomerulosclerosis with atrasentan — Chinook Therapeutics, Inc., 2025, JP [Patent]
- Treatment method for focal segmental glomerulosclerosis with atrasentan — Chinook Therapeutics, Inc., 2024, ID [Patent]
- Methods for treating focal segmental glomerulosclerosis with atrasentan (CN) — Chinook Therapeutics, 2025, CN [Patent]
- Methods of treating IgA nephropathy with atrasentan (CN) — Chinook Medical, 2021, CN [Patent]
- Biphenyl sulfonamide compounds for treating renal diseases or disorders — Travere Therapeutics, 2023, CN [Patent]
- Methods for reducing proteinuria in a human subject suffering from IgA nephropathy — University of Leicester / Omeros Corporation, 2018, WO [Patent]
- Methods for reducing proteinuria in a human subject suffering from IgA nephropathy — University of Leicester, 2021, AU [Patent]
- Methods and antibodies in treatment of focal segmental glomerulosclerosis (FSGS) — The Regents of the University of California, 2023, US [Patent]
- Reduction of soluble urokinase receptors in circulating blood — The University of Miami, 2014, JP [Patent]
- Method of treating primary focal segmental glomerulosclerosis — Genzyme Corporation, 2016, CA [Patent]
- National Kidney Foundation — FSGS Disease Overview
- European Medicines Agency — Rare Kidney Disease Regulatory Guidance
- U.S. Food and Drug Administration — Accelerated Approval Pathways
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.